Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AYX1 for postsurgical pain in TKA
NCT01731730Phase 2Completed
- Sponsor
- Adynxx, Inc.
- Start
- Jan 2013
- Primary completion
- Oct 2013
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brivoligide in Persistent postsurgical pain (PPSP) (3 arms), sponsored by Adynxx, Inc. Primary endpoints: Pain with walking during 5 meter walk test and Pain with walking during 15 meter walk test. Started Jan 2013; status: completed.
02
Drugs
brivoligide
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on NCT01731730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731730.